

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: HYTN Innovations Inc. (the “Issuer”)

Trading Symbol: HYTN

Number of Outstanding Listed Securities: 95,892,107 (as at May 31, 2026)

Date: June 2, 2026

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans³⁶⁴ unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term “Issuer” includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

- 1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

The Issuer formulates, manufactures, markets, and sells premium products that contain psychoactive and psychotropic compounds. The Issuer's mission is to become the top provider of these products in all federally regulated markets. To achieve this, the Issuer focuses on identifying market opportunities in order to quickly bring its innovative products to market through its advanced development platform.

During the month of May 2026, the Issuer actively continued general and corporate operations.

- 2. Provide a general overview and discussion of the activities of management.**

During the month of May 2026, management continued to support and oversee the Issuer’s business activities and advance the development of the Issuer’s business.

On May 7, 2026, the Issuer announced by way of news release that its Health Canada Drug Establishment Licence (DEL) has been amended following a comprehensive Good Manufacturing

Practices (GMP) inspection of its Kelowna, British Columbia Facility. See news release dated May 7, 2026, titled “*HYTN Drug Establishment Licence Expanded to Include Active Pharmaceutical Ingredients and Pharmaceutical Oils*”.

On May 29, 2026, the Issuer filed its interim financial statements and related management’s discussion and analysis for the period ended March 31, 2026 (the “**Financial Report**”).

The above referenced news release and Financial Report can be accessed under the Issuer’s profile on SEDAR+ at www.sedarplus.ca. The news release can also be accessed on the Issuer’s Canadian Securities Exchange disclosure page at <https://thecse.com/listings/hytn-innovations-inc/>.

3. **Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

None to report during the month of May 2026.

4. **Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.**

None to report during the month of May 2026.

5. **Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.**

None to report during the month of May 2026.

6. **Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.**

None to report during the month of May 2026.

7. **Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.**

None to report during the month of May 2026.

8. **Describe the acquisition of new customers or loss of customers.**

None to report during the month of May 2026.

9. **Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.**

None to report during the month of May 2026.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None to report during the month of May 2026.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None to report during the month of May 2026.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report during the month of May 2026.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None to report during the month of May 2026.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common Shares	50,000	Common shares issued pursuant to a conversion of Restricted Share Units ("RSUs")	N/A; issued pursuant to a conversion of RSUs

(1) Aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None to report during the month of May 2026.

16. Provide details of any changes in directors, officers, or committee members.

None to report during the month of May 2026.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's Form 2A - Listing Statement dated February 14, 2022 (the "**Listing Statement**"), under the heading "Item 17. Risk Factors" and in the Issuer's Management's Discussion and Analysis dated May 29, 2026 (the "**MD&A**"), under the heading "Risk Factors". The Listing Statement and the MD&A can be viewed under the Issuer's profile on SEDAR+ (www.sedarplus.ca) and on the Issuer's CSE disclosure page.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 2, 2026

Paul More

Name of Director or Senior Officer

/s/ Paul More

Signature

Chief Financial Officer and Corporate Secretary

Official Capacity

<i>Issuer Details</i> Name of Issuer HYTN Innovations Inc.	For Month End May 2026	Date of Report YYYY/MM/DD 2026/06/02
Issuer Address Unit 303 – 890 Clement Avenue Kelowna, BC, V1Y 7E4	Issuer Fax No. N/A	Issuer Telephone No. 866-590-9289
Contact Name Paul More	Contact Position Chief Financial Officer and Corporate Secretary	Contact Telephone No. 866-590-9289
Contact Email Address investments@hytn.life	Web Site Address www.hytn.life	